What is it about?
This is our broad perspective on tuberculosis drug discovery using examples of obtained through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project. We describe success and failure with target-based and phenotypic screening
Featured Image
Why is it important?
We provide brief reviews on the work done on DprE1 and PimA as well as discussion of computational approaches that can be used to predict in vivo activity. Our discussion points to the complexity in understanding the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis. We suggest that we should be doing more to leard from our prior data whether from this collaboration or elsewhere.
Perspectives
This was a very collaborative article - Katarina has worked in the area for many years and brings a terrific perspective from NM4TB and MM4TB. When we started this we wanted to ensure that failures were described as well as a more old school approach to drug discovery. This blended well with our historic analysis of molecules tested in the mouse model. We propose that future collaborative projects could follow MM4TB and learn from our experiences and provide 10 steps as part of the conclusion.
Dr Sean Ekins
Collaborations in Chemistry
Read the Original
This page is a summary of: Learning from the past for TB drug discovery in the future, Drug Discovery Today, October 2016, Elsevier,
DOI: 10.1016/j.drudis.2016.09.025.
You can read the full text:
Contributors
The following have contributed to this page
